POPLINE Document Number: 120525
Author(s):
Singh M
Saxena BB
Raghubanshi RS
Ledger WJ
Harman SM
Leonard RJ
Source citation:
CONTRACEPTION, 1997 Jan;55(1):23-33.
Abstract:
The results of a clinical study of 15 women suggest that Anuelle norethindrone (NET) biodegradable subdermal implants provide a promising alternative to both the pill and non-biodegradable implants. Study subjects were randomly assigned to receive either four pellets (174 mg NET) or five pellets (266.5 mg NET). An initial burst effect in 24-hour postimplantation serum NET levels was observed in both groups (to 3.17 +or- 0.39 ng/ml in the four-pellet group and to 3.71 +or- 0.37 ng/ml in the five-pellet group), followed by a decline, then sustained levels, and finally undetectability at 36-38 months. Menstrual cycles were normal in 65% of women in the four-pellet group and 47% of those in the five-pellet group; no subject dropped out due to abnormal vaginal bleeding patterns. The incidence of ovulation was 22% in the four-pellet group and 1% in the five-pellet group; no pregnancies occurred in either group in 24 months of observation. Plasma lipids showed reduced total and low density lipoprotein cholesterol and triglycerides. No major adverse local or systemic side effects were noted. Acceptability was good in terms of cosmetics, convenience of implantation, biodegradability, and ease of removal (if required) and most study participants expressed the desire to use NET implants as their contraceptive method of choice.
Keywords:
Research ReportIndex page
Contraception Research
Clinical Trials
Contraceptive Implants
Norethindrone
Side Effects
Contraceptive Agents, Side Effects
Women
Contraception
Family Planning
Clinical Research
Research Methodology
Contraceptive Methods
Contraceptive Agents, Progestin
Contraceptive Agents, Female
Contraceptive Agents
Treatment
Demographic Factors
Population